Skip to content

News & updates

Press Releases

MiRXES to mass produce and distribute A*STAR Singapore’s tested and proven SARS-CoV-2 RT-PCR test

April 23, 2020

MiRXES collaborates with NUS and DxD Hub to move Singapore to the forefront of global microRNA research and application

January 29, 2020

MiRXES to collaborate with Beth Israel Deaconness Medical Centre

June 26, 2018

MiRXES, Johnson & Johnson and Janssen unite for early detection of lung cancer

January 10, 2018

MiRXES partners Janssen R&D to advance early detection of diabetes

March 22, 2016

MiRXES spins out from A*STAR with novel qPCR assay platform for microRNA analysis

February 27, 2014

Media Coverage

Biotech firms race against time to get around logistical challenges
May 23, 2020 /
MiRXES leading the way in microRNA technology
May 21, 2020 /
Home-grown firms linked to pandemic work will continue to attract demand, investments
May 10, 2020 /
MiRXES’ role in Singapore’s pivot to mass COVID-19 tests
May 8, 2020 /
MiRXES is 102nd on Financial Times ranking of Asia-Pacific High Growth Companies
April 21, 2020 /
COVID-19 putting MiRXES and Singapore on global deeptech radar
April 14, 2020 /
MiRXES heeding the call for COVID-19 testing
March 30, 2020 /
MiRXES and Singapore scientists on the front lines of fight against COVID-19
March 25, 2020 /
MiRXES — A game changer in microRNA applications
March 3, 2020 /
Singapore clears Fortitude Kit SARS-CoV-2 test for clinical use
March 3, 2020 /
MiRXES to mass-produce Singapore-developed Fortitude Kit SARS-CoV-2 test kits
February 18, 2020 / ,
MiRXES named Singapore’s fastest growing company in the health sector from 2015-2018
January 15, 2020 /
Timely guidance for MiRXES from Pro-Enterprise Panel
November 7, 2019 /
GASTROClear blood test for stomach cancer first step to ending all cancer deaths
September 18, 2019 /
MiRXES has a real shot at stamping out cancer deaths
July 8, 2019 /
Seniors tested for stomach cancer with GASTROClear at free screening in Teck Ghee
May 18, 2019 /
MiRXES’ holding company raises US$40M to expand its non-invasive cancer detection technologies in Asia
November 27, 2018 /
MiRXES’ holding company clinches $55.03m funding
November 27, 2018 /
MiRXES team gets funding to ‘eliminate late-stage cancer’
November 27, 2018 /
MiRXES’ holding company launched with US$40m Series A funding
November 27, 2018 /
Promising biomedical start-ups in Singapore – MiRXES
June 28, 2018 /
MiRXES co-founder Zhou Lihan’s entrepreneurial journey
May 14, 2018 /
MiRXES collaborates with Johnson & Johnson to develop miRNA test for lung cancer
January 16, 2018 /
MiRXES aims to make cancer tests more accessible
November 21, 2016 /
Venturecraft invests in MiRXES
September 6, 2016 /
MiRXES creates alternative test for cancer
August 23, 2016 /
Screening for early stage stomach cancer with a blood test
March 21, 2016 /
Singapore scientists develop blood test to spot stomach cancer
February 12, 2016 /
Screen for stomach cancer with a blood test
February 12, 2016 /
« Prev12Next »